SBIR/STTR Research Award

Lateral Flow Assay for Diagnosis of Histoplasmosis

Award identifier 26fd22472ead3167742dbf9a91b0898173a74803950a031cd674ba52385c8210Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,819,658

Program and phase

SBIR · Phase II

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Immuno-mycologics, Inc.
Proposal award date
2015-04-15
Contract end date
2018-06-30
UEI
CN4DMLCJGCK9
Solicitation number
PA14-071
Topic code
NIAID

Research abstract

DESCRIPTION provided by applicant Progressive disseminated histoplasmosis is a common and serious opportunistic infection among individuals with HIV AIDS In many resource limited areas such as Latin America incidence rates in HIV AIDS can be andgt with mortality rates among cases andgt Successful treatment of histoplasmosis in patients with AIDS requires early diagnosis and treatment As a consequence there is a critical need for a rapid effective and low cost point of care POC diagnostic test for histoplasmosis Currently diagnosis of histoplasmosis relies on demonstration of the fungus in clinical specimens by histopathology or culture Such methods have a low sensitivity are time consuming are expensive and require trained personnel An alternative approach to diagnosis is detection of shed fungal antigens in body fluids such as blood or urine Immunoassays are a well established means to diagnose fungal and microbial infections for a broad spectrum of infectious diseases Importantly immunoassays are readily adaptable to a POC format using platform technologies such as a lateral flow assay LFA In the Phase I STTR Grant R AI entitled andquot Point of care immunoassay for diagnosis of histoplasmosis in HIV AIDSandquot a monoclonal antibody to a Histoplasma polysaccharide was developed and used to develop an LFA that accurately detects the presence of Histoplasma antigen in the urine of infected patients The goal of this Phase II project is to further develop and validate the Histoplasma LFA for definitive diagnosis of histoplasmosis in the urine of HIV AIDS infected patients in South America Criteria for success of this Phase II SBIR proposal would be the generation of data to support a k application of a diagnostic assay that would definitively detect the presence of Histoplasma in the urine of infected patients which could ultimately result in a dramatic decrease in the mortality associated with this disease PUBLIC HEALTH RELEVANCE Progressive disseminated histoplasmosis is a common and serious opportunistic infection among individuals with HIV AIDS In many resource limited areas such as Latin America incidence rates in HIV AIDS can be andgt with mortality rates among cases andgt This is a translational research study whose goal is to validate a novel lateral flow assay LFA for diagnosis of histoplasmosis in clinical patient specimens In the Phase I STTR Grant R AI entitled andquot Point of care immunoassay for diagnosis of histoplasmosis in HIV AIDSandquot a monoclonal antibody to a Histoplasma polysaccharide was developed and used to develop an LFA that accurately detects the presence of Histoplasma antigen in the urine of infected patients The success of this study will ultimately facilitate the definitive detection of Histoplasma in the urine of infected patients which could ultimately resul in a dramatic decrease in the mortality associated with this disease

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

9 SBIR/STTR records share this UEI (2011–2020). Reported award amounts total $5,280,795. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.